Stocks to Buy 2014: Just $1 Unlocks Tech's Hottest New Sector

[Editor's Note: This inside look at three of the hottest "Miracle Materials" sectors today - and one of the best stocks to buy in the rare-earth metals sector - was first published March 11 in Michael A. Robinson's Strategic Tech Investor. To get all of Robinson's research as soon as it's released, click here.]

Email

It's not often that you get a chance to get in on the "ground floor" of an entire new business.

But that's just what you have here.

In the past, you've heard me say that we are living in the "Golden Age of Materials Science." You see, without Miracle Materials – and the science that backs them – we simply wouldn't have some of the unique high-tech products we take for granted: smartphones, electric cars, and new drug therapies just to name a few.

Today, I want to talk with you about three of the Miracle Materials sectors that I'm targeting … and to tell you about one of the best super-low-priced stocks to buy – with 300% profit potential.

So let's get down to it…

Miracle Material No. 1: Synthetic DNA

I was having dinner with the chief executive officer of a biotech firm not long ago when the conversation wound around to Miracle Materials. To underscore their importance, Miracle Materials scientists are now participants very early in the product-discovery phase of the global-tech ecosystem. Advanced technologies, you see, now require breakthroughs in a wide range of materials – from polymers to metals to medical molecules.

Nowhere is this need more obvious than with the development of synthetic vaccines.

Since synthetic vaccines stem from fragments of man-made DNA, the idea is to "program" them to fight the flu or other diseases.

I see this approach as a "Disruptive Technology" that will turn the $30 billion vaccine market inside out. Besides the flu, firms in this space are working on synthetic vaccines for leukemia, HIV, malaria, hepatitis, and cancer.

Currently, no firm has a synthetic product on the market for human use. But trust me, those products are coming. Several are in clinical trials right now – just awaiting U.S. Food and Drug Administration (FDA) approval.

This field of materials science is extremely important for a couple of reasons.

Join the conversation. Click here to jump to comments…

About the Author

Michael A. Robinson is one of the top financial analysts working today. His book "Overdrawn: The Bailout of American Savings" was a prescient look at the anatomy of the nation's S&L crisis, long before the word "bailout" became part of our daily lexicon. He's a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style. His 30-year track record as a leading tech analyst has garnered him rave reviews, too. Today he is the editor of the monthly tech investing newsletter Nova-X Report as well as Radical Technology Profits, where he covers truly radical technologies – ones that have the power to sweep across the globe and change the very fabric of our lives – and profit opportunities they give rise to. He also explores "what's next" in the tech investing world at Strategic Tech Investor.

Read full bio

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK